GYKI-11679 is a new antihypertensive agent.
GYKI-11679 is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of GYKI-11679, and this effect lasts for 4 to 6 h. It is demonstrated that GYKI-11679 exerts a greater NA lowering effect in the hypothalamus than in the periphery. GYKI-11679 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment[1].
[1]. Huszti Z, et al. Influence on turnover and level of hypothalamic noradrenaline by a new antihypertensive agent (GYKI 11679). J Neurochem. 1981 Nov;37(5):1272-81.
















